webmaster-prism

About webmaster-prism

This author has not yet filled in any details.
So far webmaster-prism has created 72 blog entries.

Current and Future Oncology Management in the United States

2020-02-26T13:54:33+00:00February 7th, 2019|Categories: News|

Originally posted by the Journal of Managed Care & Specialty Pharmacy Volume 25 Issue (2) Anne Runyan, BA; Jordan Banks, MPA; and Daniele Severi Bruni, MS MKO Global Partners, Powell, Ohio. J Manag Care Spec Pharm, 2019 Feb;25(2):272-281. Abstract BACKGROUND: The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital [...]

Current and Future Oncology Management in the United States

2020-02-26T13:56:46+00:00February 1st, 2019|Categories: Blog|Tags: , |

The cost of treating cancer patients is high and rising in the United States. Payers are exposed to cost through doctor visits, laboratory tests, imaging tests, radiation treatment, drugs, hospital stays, surgery, home care, transportation and travel, and caregiving. This study focuses on the cost of medication from the viewpoint of U.S. payers. Although new tools for managing these costs have been gaining attention, prices continue to rise, and [...]

Innovative Access Agreements

2020-02-26T14:01:42+00:00January 1st, 2019|Categories: Blog|Tags: , , |

A potential payer solution for Cell & Gene Therapies A US and European perspective Payer concerns over increasing cost of therapies and uncertainty of clinical data have led to a growing interest in market access tools. These tools have many names and definitions, often referred to as innovative (IAA) or alternative access agreements (AAA). For the purpose of this review we will refer to them collectively as IAA. The [...]

NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab

2019-08-12T15:42:16+00:00November 1st, 2018|Categories: News|

With the recent patent expiry of Humira® (adalimumab) in Europe, NHS England last week published a press release reiterating their goal of realizing £300 million in annual savings through the adoption of best value biologic medicines (originator or biosimilar) by 2021. With more than 46,000 patients in the UK and an annual cost of greater than £400 million, Humira represents the largest spend on a single drug by the NHS and a significant opportunity [...]

Comments Off on NHS England targeting £150 million in savings through rapid adoption of biosimilar adalimumab

Failure to Launch: Five key reasons that biosimilars have failed to gain traction in the US market

2020-02-26T14:02:40+00:00November 1st, 2018|Categories: Blog|Tags: , |

Although biosimilars have taken off in Europe, they have yet to gain significant traction in the United States. More than thirty biosimilars have been approved and twenty-six are marketed in Europe. In the US, there are only eleven biosimilars approved with only five marketed: Zarxio, Fulphila, Retacrit, Renflexis, and Inflectra. Read the full report by downloading this paper. Download White Paper

Two Labs Acquires Pennside Partners Ltd.

2020-02-26T14:03:37+00:00October 23rd, 2018|Categories: Blog|Tags: , , |

We’re excited to share today that as of  October 18, 2018, Two Labs has acquired Pennside Partners Ltd., a leading international provider of market insights, benchmarking, and competitive intelligence services for the pharmaceutical, biotech, and medical device sectors. This acquisition enhances Two Labs’ suite of services with complementary competitive intelligence services and extends its capabilities into clinical product insights allowing us to better meet clients’ evolving needs. At our [...]

Two Labs Acquires Pennside Partners Ltd.

2019-08-12T15:17:30+00:00October 23rd, 2018|Categories: News|

Company expands services suite with addition of market insights, benchmarking and competitive intelligence COLUMBUS, Ohio, (October 23 2018) - Industry-leading pharmaceutical services company, Two Labs, today announced it has acquired Pennside Partners Ltd., an international provider of market insights, benchmarking and competitive intelligence services for the pharmaceutical, biotech, and medical device sectors. Terms of the agreement were not disclosed. The partnership is a testament to a shared commitment to improving patients' quality of [...]

Everything You Need to Know About the DSCSA in 2018

2020-02-07T15:37:23+00:00September 24th, 2018|Categories: Blog|

By now, you’ve probably heard of the DSCSA. Since its passing in 2013, the act has been the talk of the industry as it continues to reshape the distribution landscape. However, because of the staggered roll out, varied enforcement dates, and multiple moving pieces, the DSCSA can be tricky. To help you keep track of the most important changes, we have mapped out the key things to know [...]

Comparison of US and EU approaches to Oncology Management

2020-02-07T15:38:44+00:00September 10th, 2018|Categories: Blog|

It was great meeting all of you who were able to stop by our booth in Glasgow! It was a great experience to present our findings to the industry innovators at ISPOR. The themes of early data evaluation and subsequent real word evaluations for management decision-making emerged throughout the day. We look forward to continuing our work in understanding trends and the feasibility of management strategies globally. [...]

Key Learnings on Pathways of Care

2020-02-07T15:40:08+00:00August 1st, 2018|Categories: Blog|

Oncology is a high cost and high management priority disease state for US payers, however, ability to control cost in this space is limited. MKO Global Partners, a Two Labs Company, conducted previous research that suggests oncology drugs are primarily managed to label and only occasionally are there policies in place to restrict or prefer certain agents. However, new ways to control the cost of oncology care are emerging [...]

Contact Info

110 Riverbend Avenue, Suite 100, Powell, OH 43065

Phone: 614.389.4004

Fax: 866.259.4324

Recent News